Patent cliffs are predictable. The response rarely is.

Loss of exclusivity is one of the most foreseeable events in pharmaceutical development. The date is known years in advance. The revenue impact is well understood. The strategic options — new formulations, new indications, new markets, combination products, follow-on compounds — are finite and well-documented. And yet organizations consistently underinvest in lifecycle strategy until the window for meaningful action has narrowed significantly.

The reasons are partly structural and partly behavioral. Structurally, lifecycle strategy competes for resources with late-stage development programs that have clearer near-term milestones and more visible executive sponsorship. Behaviorally, the urgency of a patent cliff that is five years away is easy to discount when there are programs in Phase III that need attention today.

The organizations that manage this well treat lifecycle strategy as a portfolio discipline, not a product-level activity. They maintain a systematic view of their exclusivity landscape, model the revenue implications of different scenarios, and make explicit decisions about where to invest in lifecycle extension and where to accept the cliff.

This requires a level of portfolio visibility that many organizations lack. It also requires a governance process that can hold lifecycle strategy decisions alongside pipeline investment decisions — comparing them on a common framework rather than managing them in separate silos.

The cost of getting this wrong is significant. Organizations that arrive at a patent cliff without a credible lifecycle strategy face a combination of revenue decline, pipeline gaps, and constrained options that is difficult to recover from quickly. The organizations that get it right start earlier than feels necessary and treat the predictability of the event as an asset rather than a given.